Loading...
Cipla Limited — Teicoplanin Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #4 for Teicoplanin · $234.7K export value · DGFT Verified
Cipla Limited is the #4 Indian exporter of Teicoplanin with $234.7K in export value and 11 verified shipments. Cipla Limited holds a 3.7% market share in Teicoplanin exports across 1 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| SRI LANKA | $1.2M | 43 | 24.1% |
| HUNGARY | $1.1M | 23 | 24.0% |
| SOUTH AFRICA | $1.1M | 21 | 21.9% |
| GERMANY | $336.9K | 7 | 7.0% |
| RUSSIA | $250.0K | 5 | 5.2% |
| LEBANON | $215.0K | 34 | 4.5% |
| NEPAL | $152.3K | 16 | 3.2% |
| VENEZUELA | $121.7K | 9 | 2.5% |
| CUBA | $100.0K | 2 | 2.1% |
| SPAIN | $100.0K | 2 | 2.1% |
India exports Teicoplanin to 44 countries. The top destination is SRI LANKA (24.1%), followed by HUNGARY and SOUTH AFRICA.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| SLIM PHARMACEUTICALS (PVT) LTD, | SRI LANKA | $245.7K | 14 |
| YADEN INTERNATIONAL (PVT) LTD | SRI LANKA | $215.1K | 5 |
| MEDPRO PHARMACEUTICA PTY LTD | SOUTH AFRICA | $209.1K | 6 |
| AUSTELL PHARMACEUTICALS (PTY) LTD, | SOUTH AFRICA | $195.1K | 4 |
| AUSTELL PHARMACEUTICALS ( PTY) LTD | SOUTH AFRICA | $150.0K | 3 |
| HANSE SERVICE INTERNATIONALE | GERMANY |
India exported $5.7M worth of Teicoplanin through 310 shipments from 60 suppliers to 44 countries, serving 108 buyers globally. Cipla Limited contributes $234.7K to this total, accounting for 3.7% of India's Teicoplanin exports.
Cipla Limited's average Teicoplanin shipment value is $21.3K per consignment, based on 11 shipments totaling $234.7K.
Cipla Limited ranks #4 among 60 Indian Teicoplanin exporters with a 3.7% market share. The top 3 exporters are GUFIC BIOSCIENCES LIMITED ($4.3M), FLAGSHIP BIOTECH INTERNATIONAL PRIVATE LIMITED ($250.0K), JODAS EXPOIM PRIVATE LIMITED ($250.0K). Cipla Limited processed 11 shipments to 1 destination countries.
What Cipla Limited must comply with to export Teicoplanin to its top destination countries
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Approval Process
Marketing Authorisation via Decentralized or Mutual Recognition Procedure under EU Directive 2001/83/EC. CTD Module 1–5 dossier required.
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | FLAGSHIP BIOTECH INTERNATIONAL PRIVATE LIMITED | $250.0K | 5 | 3 | $50.0K |
| 3 | JODAS EXPOIM PRIVATE LIMITED | $250.0K | 5 | 1 | $50.0K |
| 4 | CIPLA LIMITED ★ | $234.7K | 11 | 1 | $21.3K |
| 5 | NEON LABORATORIES LIMITED | $215.1K | 6 | 2 | $35.8K |
| 6 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 69 | 22.3% |
| SAHAR AIR | 67 | 21.6% |
| NHAVA SHEVA SEA (INNSA1) | 27 | 8.7% |
| DELHI AIR | 24 | 7.7% |
| Bombay Air | 22 | 7.1% |
| DELHI AIR CARGO ACC (INDEL4) | 16 | 5.2% |
| CHENNAI AIR CARGO ACC (INMAA4) | 8 | 2.6% |
| HYDERABAD AIR | 8 | 2.6% |
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Teicoplanin, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Teicoplanin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Teicoplanin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
| $150.0K |
| 3 |
| MEDICUBA, S.A. | CUBA | $100.0K | 2 |
| PEOPLE'S BANK, | SRI LANKA | $100.0K | 2 |
| AUSTELL PHARMACEUTICALS ( PTY) LIMITED | SOUTH AFRICA | $100.0K | 2 |
| M/S. OOO JODAS EXPOIM.. | RUSSIA | $100.0K | 2 |
India's Teicoplanin is purchased by 108 buyers worldwide. The top buyer is SLIM PHARMACEUTICALS (PVT) LTD, (SRI LANKA), followed by YADEN INTERNATIONAL (PVT) LTD and MEDPRO PHARMACEUTICA PTY LTD.
Timeline: 12–18 months via Decentralized Procedure
GMP & Export Requirements
EU GMP (EudraLex Vol. 4); GMP certificate from EU competent authority; WHO Prequalification accepted as supporting evidence
Certificate of Pharmaceutical Product (CPP) from CDSCO; Written Confirmation for API export per EU requirements; EU FMD serialization mandatory
Note: Indian manufacturers must hold EU GMP certificate. EU Falsified Medicines Directive (FMD) serialization and tamper-evident packaging mandatory.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| VENUS REMEDIES LIMITED |
| $134.1K |
| 18 |
| 9 |
| $7.4K |
Cipla Limited ranks #4 among 60 Indian Teicoplanin exporters. Average shipment value of $21.3K compared to the market average of $95.7K. The closest competitors by value are FLAGSHIP BIOTECH INTERNATIONAL PRIVATE LIMITED and JODAS EXPOIM PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 44+ countries, 108+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Teicoplanin. For current shipment-level data, contact TransData Nexus.